Rubicon Research Limited (NSEI: RUBICON)
Health Care · Pharmaceuticals · IN
Rs1,548.50
-5.05% today · +146.5% 1Y
Rubicon Research Limited (NSEI: RUBICON) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.65B.
Over the last twelve months the share price has gained 146.5%, trading between 570.75 and 1.90K.
Tweenvest scores Rubicon Research Limited across four factors: quality 72/100, value 26/100, growth 100/100, dividend 92/100. Its strongest factor is growth.
RUBICON price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.65B
- Revenue (TTM)
- $204.73M
- P/E
- 88.16
- EPS
- 17.56
- Dividend yield
- 0.10%
- Beta (5Y)
- —
- 52-week high
- Rs1,899.00
- 52-week low
- Rs570.75
- Avg volume (3M)
- —
- Shares outstanding
- 165.53M
- Employees
- —
- Next earnings
- —
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Neuland Laboratories LimitedBSE: 524558 | $2.77B | Rs20,879.85 | -2.87% |
| Joincare Pharmaceutical Group Industry Co.,Ltd.SHSE: 600380 | $2.77B | CN¥10.13 | +2.32% |
| Piramal Pharma LimitedNSEI: PPLPHARMA | $2.70B | Rs196.88 | -0.55% |
| Acutaas Chemicals LimitedNSEI: ACUTAAS | $2.67B | Rs3,160.60 | -1.12% |
| MBX Biosciences, Inc.NasdaqGS: MBX | $2.56B | $52.89 | -0.66% |
| China Resources Double-Crane Pharmaceutical Co.,Ltd.SHSE: 600062 | $2.53B | CN¥16.44 | +1.23% |
| Supernus Pharmaceuticals, Inc.NasdaqGM: SUPN | $2.48B | $42.68 | +0.02% |
| Curaleaf Holdings, Inc.TSX: CURA | $2.47B | CA$13.31 | -6.33% |
Figures last refreshed Oct 11, 2026.